Insider Trading Arrangements |
3 Months Ended |
|---|---|
|
Jun. 30, 2026
shares
| |
| Trading Arrangements, by Individual | |
| Non-Rule 10b5-1 Arrangement Adopted | false |
| Rule 10b5-1 Arrangement Terminated | false |
| Non-Rule 10b5-1 Arrangement Terminated | false |
| Elizabeth Yeu-Lin [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | On June 1, 2026, Elizabeth Yeu-Lin, our Chief Medical Officer, adopted a Rule 10b5-1 trading arrangement (the “Yeu-Lin Plan”) intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The Yeu-Lin Plan provides for the potential sale of up to 9,506 shares of common stock held by Ms. Yeu-Lin between September 1, 2026 and August 31, 2027. |
| Name | Elizabeth Yeu-Lin |
| Title | Chief Medical Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | June 1, 2026 |
| Expiration Date | August 31, 2027 |
| Arrangement Duration | 456 days |
| Aggregate Available | 9,506 |
| Spouse Of Ms. Yeu-Lin [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | Also on June 1, 2026, the spouse of Ms. Yeu-Lin adopted a Rule 10b5-1 trading arrangement (the “Spousal Plan”) covering shares of the Company's common stock in which Ms. Yeu-Lin has an indirect pecuniary interest reportable under Section 16 of the Exchange Act. The Spousal Plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) and provides for the potential sale of up to 6,360 shares of the Company's common stock, between September 1, 2026 and September 1, 2027. |
| Name | spouse of Ms. Yeu-Lin |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | June 1, 2026 |
| Expiration Date | September 1, 2027 |
| Arrangement Duration | 457 days |
| Aggregate Available | 6,360 |